You have accessJournal of UrologyTrauma/Reconstruction/Diversion: Ureter (including Pyeloplasty) and Bladder Reconstruction (including fistula), Augmentation, Substitution, Diversion II (MP53)1 Sep 2021MP53-13 PROGNOSTIC FACTORS FOR OVERALL SURVIVAL IN MALIGNANT URETERAL OBSTRUCTION Michael Creswell, Jillian Egan, J Bradley Mason, Christopher Dall, Tamir Sholklapper, Lan Anh Galloway, Joanna Orzel, Harry Lee, Sameer Desale, and Lambros Stamatakis Michael CreswellMichael Creswell More articles by this author , Jillian EganJillian Egan More articles by this author , J Bradley MasonJ Bradley Mason More articles by this author , Christopher DallChristopher Dall More articles by this author , Tamir SholklapperTamir Sholklapper More articles by this author , Lan Anh GallowayLan Anh Galloway More articles by this author , Joanna OrzelJoanna Orzel More articles by this author , Harry LeeHarry Lee More articles by this author , Sameer DesaleSameer Desale More articles by this author , and Lambros StamatakisLambros Stamatakis More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002083.13AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Ureteral obstruction is common in the setting of advanced gynecologic malignancies (GM). Prior studies have investigated prognostic factors associated with overall survival (OS) for patients with malignant ureteral obstruction (MUO), but data is overall sparse. This information is important for appropriate patient counseling regarding the risks and benefits of urinary diversion in this setting. We attempted to identify prognostic factors for OS and stent failure (SF) in patients with MUO from GM. METHODS: A retrospective review of 126 patients with MUO from GM at two academic centers was performed. Clinical and laboratory data for patients > 18 years and a diagnosis of hydronephrosis and GM from 2011-2019 were collected. Factors related to OS were determined using a Cox regression proportional hazard model. In patients with incomplete survival data (n=30), hospice was used as a surrogate for death. RESULTS: OS of <6 months, 6-12 months, and >12 months was 52%, 8%, and 40%, respectively. On univariate analysis, age at diagnosis, Charlson Comorbidity Index (CCI) > 8, advanced clinical stage, ascites, pleural effusion, albumin at intervention and hemoglobin at intervention were associated with poor OS. OS was higher for those who received ureteral stent as compared to those with no intervention or percutaneous nephrostomy (PCN) placement. There was no survival difference based on severity of hydronephrosis, occurrence of SF, or creatinine at the time of intervention. CONCLUSIONS: OS in patients with MUO is poor. 52% will die or be in hospice within 6 months of hydronephrosis. Several prognostic factors for poor survival were identified. Ureteral stenting was associated improved OS, but selection bias likely contributed to this result. Additional studies are needed to clarify this finding. These data can be utilized to counsel patients regarding outcomes after urinary diversion in the setting of MUO. Source of Funding: None © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e943-e944 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Michael Creswell More articles by this author Jillian Egan More articles by this author J Bradley Mason More articles by this author Christopher Dall More articles by this author Tamir Sholklapper More articles by this author Lan Anh Galloway More articles by this author Joanna Orzel More articles by this author Harry Lee More articles by this author Sameer Desale More articles by this author Lambros Stamatakis More articles by this author Expand All Advertisement Loading ...
Read full abstract